EssilorLuxottica closes at the bottom of the Paris index in mid-afternoon, while the CAC 40 edges slightly higher. The stock is losing momentum after a sharp rebound that began with the publication of its quarterly sales.
A decline that brings the stock back to its long-term average
The stock EssilorLuxottica falls 3.07% to €181.85, the largest decline in the index, while the CAC 40 gains 0.28%. This pullback follows a month of strong recovery (+24.26%), which had already run into resistance at €191.95 in early November, as the stock had shown on November 6.
The price is now close to its MM200 at €180.99 (a gap of 0.48%), while remaining above its MM20 at €177.04 (+2.72%). Over one year, however, the stock is still down 41.68%.
Third-quarter sales and the group's business momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The recent rebound is supported by third-quarter revenue, published on October 20, up 7.2% at constant exchange rates. At that date, the group indicated that its direct-to-consumer segment had grown 10.6% in the third quarter, with same-store sales up 6.8%.
Myopia management solutions posted +24% over nine months, and the traditional activities (Eyecare and Medtech) recorded growth above 6%. On October 23, S&P had also raised the group's credit rating to A+, with a stable outlook. Technically, the next level to watch remains resistance at €193.80.
SectorDispositifs médicaux et optique›Optique / lunetterie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 22 304 millions d'euros
Quarterly revenue: 22 304 millions d'euros
Revenue growth: 6,8 %
Opportunities identified
Le portefeuille des solutions de gestion de la myopie a progressé de +24 % sur les neuf premiers mois
Les activités traditionnelles (Eyecare & Medtech) ont progressé à un rythme supérieur à +6 %, tant au T3 que sur les neuf premiers mois
Segment Direct to Consumer en hausse de +10,6 % au T3, ventes à magasins comparables à +6,8 %
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
